Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study

Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, has demonstrated robust weight loss and glycemic benefits in randomized controlled trials. However, real-world data comparing its effectiveness and tolerability in obese adults with...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Prabhat Kumar Agrawal, Shambo Samrat Samajdar, Ruchika Garg, Gaurav Gupta, Ashish Gautam, Noor Husain, Shatavisa Mukherjee, Sandipta Kumar Panda
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wolters Kluwer Medknow Publications 2026-01-01
Edice:	Journal of Mid-Life Health
Témata:	glucagon-like peptide-1 receptor agonist obesity tirzepatide type 2 diabetes weight loss
On-line přístup:	https://journals.lww.com/10.4103/jmh.jmh_373_25
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!